Integrated Islet Distribution Program (U24) - 2021

项目摘要/摘要 人胰岛是预防、治疗和治疗糖尿病的重要研究资源。 糖尿病的病理生理学。最近的数据突显了小鼠和小鼠之间的重要差异 人类胰岛，证实继续需要进入人类胰岛，作为糖尿病的黄金标准 研究。希望之城(COH)正在申请将这一U24更新保留为综合岛屿分布 计划协调中心(IIDP CC)在未来5年内继续提供人力资源分配 身体胰岛和辅助组织供世界各地的研究人员进行生物医学研究。我们的提案充分利用了 NIH在过去19年中所做的重大投资已经建立并成功地维持了 COH的IIDP。从高质量的胰岛隔离中心(IICS)的资格认证和审核，到预测， 跟踪和满足调查人员的需求，自2002年以来，我们经验丰富的团队已与20个不同的 胰岛隔离实验室协调将3.3亿多个等量的胰岛分配给400多个 自2002年以来，来自16个国家的调查人员为767份同行评审的出版物提供了支持。通过此次更新 我们将继续与我们的5个高质量的IICS分包，以隔离和分发人类胰岛和附属 组织通过我们先进的电子胰岛分配系统(IAS)。我们将继续管理审查过程 用于小岛收据、试点研究和机会池资金。我们将进一步加强我们的IAS以广播报价 在网上，以公平、公平和对时间敏感的方式，通知经批准的等待研究人员可获得胰岛。 资讯基建发展计划会继续维持现有的成本回收制度，向小岛收取订阅费。 研究人员，自实施订阅费以来共获得9,303,950美元，以抵消 IICS的胰腺加工费用。我们会继续密切监察和协助改善 通过人类胰岛表型鉴定计划(HIPP)的延续，分发的胰岛质量 对每个胰岛分离的样本进行化验。IIDP刚刚增加了人类小岛基因分型倡议 (High)对每个分离株也进行基因分型。表型和基因分型数据，以及联合国操作系统的数据，内容广泛 捐赠者和胰岛隔离数据将通过IIDP的在线访问提供给经批准的调查人员 研究数据库，申请科学家获得IIDP和NIDDK批准。调查人员可以轻松地搜索 所需数据，选择筛选条件，保存他们的搜索，并下载集成的IIDP数据以供探索 分析。通过我们经过验证的最先进的管理、业务、技术、统计、质量保证， 和信息学过程和工具，人类小岛的可及性对于调查人员进行 糖尿病研究将得到保障。我们将继续为以下项目提供不可或缺的研究资源 糖尿病研究界通过确保IIDP保持稳定、技术不断进步 增强并充分响应研究社区的小岛需求，促进下一代 预防和治疗糖尿病的科学实验。

PROJECT SUMMARY / ABSTRACT Human pancreatic islets are an essential research resource for research on the prevention, treatment, and pathophysiology of diabetes mellitus. Recent data have highlighted important differences between murine and human islets, substantiating the continued need for access to human islets, as the gold standard in diabetes research. City of Hope (COH) is applying for this U24 renewal to remain as the Integrated Islet Distribution Program Coordinating Center (IIDP CC) for the next 5 years, to continue to provide distribution of human cadaveric islets and ancillary tissue for biomedical research to researchers worldwide. Our proposal leverages the significant investment made by NIH over the last 19 years that has established and successfully maintained the IIDP at COH. From qualification and auditing of high-quality Islet Isolation Centers (IICs), to forecasting, tracking, and meeting the needs of investigators, since 2002 our experienced team has worked with 20 different islet isolation laboratories to coordinate the distribution of over 330 million islet equivalents to more than 400 investigators across 16 countries since 2002, supporting 767 peer reviewed publications. Through this renewal we will continue to subcontract with our 5 highly qualified IICs to isolate and distribute human islets and ancillary tissue via our advanced electronic Islet Allocation System (IAS). We will continue to manage the review process for islet receipt, pilot studies, and Opportunity Pool funding. We will further enhance our IAS to broadcast offers online and notify approved waiting researchers of islet availability, in a fair, equitable and time sensitive manner. IIDP will continue to maintain the existing cost recovery system through subscription fees collected from islet researchers, which has garnered a total of $9,303,950 since the implementation of subscription fees to offset the expenses of pancreatic processing for the IICs. We will continue to closely monitor and help to improve the quality of islets distributed, through the continuation of the Human Islet Phenotyping Program (HIPP) that conducts assays on a sample from each islet isolation. IIDP has just added a Human Islet Genotyping Initiative (HIGI) to genotype each isolation as well. Phenotyping and genotyping data, as well as UNOS data, extensive donor and islet isolation data, will be made available to approved investigators through online access to the IIDP Research Data Repository, with IIDP and NIDDK approval of applying scientists. Investigators can easily search the required data, select filter criteria, save their searches, and download the integrated IIDP data for exploratory analyses. Through our proven state-of-the-art administrative, business, technical, statistical, quality assurance, and informatics processes and tools, the accessibility of human islets for investigators conducting essential diabetes mellitus research will be secured. We will continue to provide an indispensable research resource for the diabetes research community by ensuring that the IIDP remains stable, technologically advanced, continually enhanced, and fully responsive to the islet needs of the research community, promoting the next generation of scientific experimentation toward the prevention and treatment of diabetes.